Home survival veterans prisoners new_drugs hcv_handout dr_cecil_cv hbv_info pegIntron cirrhosis pegasys resources infergen maint-inf Who has HCV?

 

email Dr. Cecil

 

CURRICULUM VITAE


NAME: Bennet Downs Cecil III, M.D.


PROFESSIONAL ADDRESS:
Hepatitis C Treatment Centers   

1009A Dupont Square N
Louisville, KY 40207
(502)-894-9950
FAX: (502)-894-9991

BIRTH: April 30 1952
Oxnard, California

MARITAL STATUS:
Married to Rose Kriss Cecil

EDUCATION:
May 1973
BA with honors
Major in ChemistryUniversity of Louisville
May 1977
M.D.
University of Louisville School of Medicine

July 1977 to June 1979
Resident in Pathology
Duke University Medical Center

July 1979-Jan 1981
Resident in Internal Medicine
Moses Cone Memorial Hospital
Greensboro, North Carolina
Affiliated with the University of North Carolina

July 1987-June 1989
Fellow (Gastroenterology/Hepatology)
University of Louisville
Affiliated Hospitals
Louisville, KY 40292
Chief: Richard Redinger, M.D.

PROFESSIONAL EXPERIENCE:
March 1982-May 1987
Internal Medicine Solo Practice
Danville, Kentucky July 1989-May 1996


Private Practice Gastroenterology/Hepatology
Louisville Kentucky September 1996-May 1997


Primary Care Blue Clinic
Ireland Army Hospital
Fort Knox, Kentucky Sept 1996-May 1997


Assistant Professor of Medicine
University of Louisville School of Medicine
Chief: Gastroenterology/Hepatology
Louisville VAMC 1997-1998


Louisville, Kentucky May 1998- Present
Assistant Clinical Professor of Medicine
University of Louisville School of Medicine


Physician
Louisville VAMC
Louisville, Kentucky
December 1998-Present


Corporate Medical Director
Hepatitis C Treatment Centers Inc.
Louisville, Kentucky

BOARD CERTIFICATIONS:
Diplomate American Board Internal
Medicine 1982
Diplomate American Board
Gastroenterology 1989

HONORS AND AWARDS:
Dr. Morris Newberg Scholarship Award (First in medical school class in Internal Medicine) WEB SITE: www.hepatitisdoctor.com

PUBLICATIONS:
1. Cecil B, Woodard B, Mickey DD, et al: Renal Carcinosarcoma. Ultrastructure and transplantation into athymic mice. Arch Pathol Lab Med 1980; May 104(5): 276-9.
2. Cecil B, Larson G, Sewell C, Redinger RR: Abdominal pain from intestinal duplication. J Clin Gastroenterology 1990; Feb. 316-319.
3. Lee J David, Cecil Bennet D, Brown Paul E, Wright Richard A: A Cohen Test does not predict outcome in achalasia after pneumatic dilation. Gastrointestinal Endoscopy 1992; Aug 39(2): 157-60.
4. Results of methylene- blue directed biopsy is similar to conventional biopsy for the diagnosis of intestinal metaplasia and dysplasia in Barrett’s esophagus Mukunda B Ray, Stephanie Mayfield-Stokes, Bennet Cecil, Bahram Forouzandeh, April Davis, Mark Wilson, John M Wo: abstract presented at ASGE Topic Forum DDW Orlando FLA May 18, 1999
5. Bennet D. Cecil Individualized treatment of hepatitis C patients with Rebetron AASLD Abstract 1844 Hepatology, Vol 30, No. 4, Pr 2, 1999 621A
6. Bennet D. Cecil, Phyllis Slone, Stephanie Mayfield-Stokes, Carlo Tamburro Hepatitis C antibodies do not predict cirrhosis or severe fibrosis in alcoholics AASLD Abstract 1843 Hepatology, Vol 30, No. 4, Pt 2, 1999 621A
7 Anthony Martin, P Wilfredo Canchis, Carlo Tamburro, Philp Fortwengler, Bennet Cecil, Allen Cox, Edward Adler et al. Combination therapy with low dose interferon and ribavirin in naïve patients with hepatitis C. AASLD Abstract 1839. Hepatology, Vol 30, No 4 Pt 2.
8. Bennet D. Cecil, Mary Lavelle. Elevated weight is a common reason for
Rebetron failure in veterans: Failure can be changed to success by increasing the interferon dose. AASLD Poster Presentation #260 Gastroenterology 118 No 4 Suppl 2 part 1 of 2
9. Bennet D. Cecil, Tami Hill, Mary Lavelle. Hepatitis C patients should be given individualized combination therapy (interferon plus ribavirin) to reach an undetectable HCV-RNA and then treated and additional 20 weeks. AASLD abstract Gastroenterology 118 No 4 Suppl 2 part 2 of 2
10. Bennet D. Cecil, Tami Hill. Individualized therapy with Infergen and
compounded ribavirin is an effective and economical treatment for hepatitis C. AASLD abstract 6486 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
11. Bennet D. Cecil, Mary Lavelle, Marylee Rothschild, John Burke A systematic organized team approach with individualized car of each hepatitis C patient allows successful treatment of US veterans with hepatitis C. AASLD abstract 6487 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
12. Bennet D. Cecil, Mary Lavelle. Causes of death in 93 US veterans with hepatitis C. AASLD abstract 6488 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
13. Bennet D. Cecil, Mary Lavelle, Marylee Rothschild, John Burke. Rebetron at standard doses is not effective in US veterans with hepatitis C. Failure is converted to success with individualized therapy. Abstract 6489
Gastroenterology 118 No 4 Suppl 2 part 2 of 2
14. Bennet D. Cecil, Tami Hill Mary Lavelle. Plotting the log of HCV-RNA versus time is a useful method to monitor treatment of hepatitis C patients and to guide dose modifications. AASLD abstract 6490 Gastroenterology 118 No 4 Suppl 2 part 2 of 2
15. Bennet D. Cecil, Mary Lavelle. Recent Advances in Hepatitis C J Ky Med Assoc 2000 Oct;98(10):440-4
16. Bennet Cecil, Tami Hill, Mary Lavelle Decompensated hepatitis C cirrhotic patients can be safely treated with titrated doses of interferon and ribavirin; they have a highly significant HCV-RNA response to treatment. Supplement to Hepatology, 30, No. 4 Pt 2 2000 AASLD abstract1570
17. Bennet Cecil. Individualized Antiviral therapy Using Viral Kinetics for Hepatitis C Patients. Louisville Medicine 2001 July;49 (2):83-84
18. Poster Presentation AASLD 2001 Dallas Texas. Bennet Cecil, Mary Lavelle. Individualized hepatitis C therapy of military veterans: Interferon dose escalation improves the sustained response rate.
19. Bennet Downs Cecil, Mary Lavelle. Individualized Hepatitis C therapy of 298 military veterans permits cure in about one fourth of patients. AASLD Abstract 1683 Hepatology, Vol36, No 4, Pt 2.
20. Bennet Downs Cecil, Mary Lavelle. Successful antiviral therapy of patients with HCV cirrhosis saves lives. AASLD Abstract 1682 Hepatology, Vol36, No 4, Pt 2, 2002
21. Bennet Downs Cecil, Mary Lavelle. PegIntron 210 mcg twice weekly allows about one third of poor responders on 210 mcg weekly to become treatment responders (HCV-RNA < 50 IU/ml) AASLD Abstract 1685 Hepatology, Vol36, No 4, Pt 2.
22. Bennet Downs Cecil, Mary Lavelle. Many patients with liver cancer from HCV cirrhosis have a curable infection. AASLD Abstract 1686 Hepatology, Vol36, No 4, Pt 2, 2002.
23. Bennet Downs Cecil. Tenofovir 300 mg daily is effective in patients with chronic HBV who fail lamivudine. AASLD Abstract 1868 Hepatology, Vol36, No 4, Pt 2, 2002
24. Bennet Downs Cecil. Many treatment responders fail because Medicaid HMO cancels treatment. AASLD Abstract 1745 Hepatology, Vol36, No 4, Pt 2, 2002
25. Bennet Cecil, Mary Lavelle, Mary Helen Stovall, Durenda Plummer, Locquetta White, William Fochtman, Regina Smallwood, Jennifer French, Kenneth Chitwood, Rebecca Barnett, Rebecca Fain, Sheila Bisinger, Angela Newlin. Directly observed therapy (DOT) using initially low doses of PegIntron is a useful method for HCV infected veterans. AASLD Abstract 1684 Hepatology, Vol36, No 4, Pt 2.                                                26. 26. Bennet Cecil, Mary Lavelle. Recent advances in hepatitis C. JKY Med Assoc 2000 Oct, 98(10) 440-4       27.B D Cecil, M Lavelle. Sustained viral response improves survival with either compensated or decompensated hepatitis C. Oral Presentation EASL Conference April 14th 2005, Paris France. Abstract 21  J  Hepatology, Supplement No. 2 Vol. 42, 2005.                                                                                          28.Timothy R. Morgan, David G. Weiss, Bernard Nemchausky, Eugene R. Schiff, Bhupinder Anand, Francis Simon, Jayashri Kidao, Bennet Cecil et al. Colchicine Treatment of Alcoholic Cirrhosis: A Randomized, Placebo-Controlled Clinical Trial of Patient Survival. Gastroenterology 2005;128;882-890.                             29. Bennet Cecil, Mary Lavelle. Sustained viral response improves the  natural history of hepatitis C patients. Poster presentation abstract P-10. 12th International Symposium one hepatitis C virus and related viruses. Montreal, Canada. October 2-6, 2005. Abstract book, p 78.

RESEARCH
Coinvestigator VA Cooperative Study 391. Effect of Polyunsaturated Lecithin on Liver Fibrosis.
Coinvestigator VA Cooperative Study 352. Colchicine in the Treatment of Alcoholic Cirrhosis of the Liver.
Coinvestigator Protocol R97-024. Intron A + Ribavirin for Treatment of Patients with Chronic Hepatitis C not Previously Treated with Interferon.
Coinvestigator Protocol R96-419. Intron A + Ribavirin for Treatment of Patients with Interferon –Refractory or Interferon-Relapsed Chronic Hepatitis C.
Two protocols using Infergen monotherapy
Two protocols using Pegasys plus ribavirin

One protocol using Pegasys plus thymosin
One protocol using PegIntron plus ribavirin

MEDICAL LICENSE:

Kentucky 21721

MEMBERSHIPS:
American Gastroenterological Association
Jefferson County Medical Society
Kentucky Medical Association